C-reactive protein in hypertensive disorders in pregnancy

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 3, 2006, Pages 330-337

  Paternoster, Delia M ^a,b   Fantinato, Sara ^a   Stella, Andrea ^a   Nanhornguè, Kimta Ngaradoumbe ^a   Milani, Massimo ^a   Plebani, Mario ^a   Nicolini, Umberto ^a   Girolami, Antonio ^a  

^a Department of Gynecology and Human Reproduction ^*

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

CRP; Flogosis; Hypertensive disorders in pregnancy

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; BIRTH WEIGHT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; PATHOGENESIS; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; BODY WEIGHT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; INFLAMMATION; PRE-ECLAMPSIA; PREGNANCY;

EID: 33748740812     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606291382     Document Type: Article

References (29)

1. Rochat R. Maternal mortality in the United States: Report from the Maternal Mortality Collaborative. Obstet Gynecol 1988;72:91.
2. Shearman RP. Trends in maternal mortality in Australia: Relevance in current practice. Aust NZ J Obstet Gynecol 1990;30:15.
3. Walzer JJ. Pre-eclampsia. Lancet 2000;356:1260.
4. Diagnosis and Management of Preeclampsia and Eclampsia. ACOG practice bulletin n.33, January 2002.
5. Redman CWG, Sacks GP, Sargent IL. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499.
6. Conrad KP, Miles TM, Enyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998;40:102.
7. Benyo DF, Smarason A, Redman CW, et al. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001;86:2505.
8. Tjoa ML, van Vugt JM, Go AT, et al. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J Reprod Immunol 2003:29.
9. Wolf M, Kettyle E, Sandler L, et al. Obesity and preeclampsia: The potential role of inflammation. Obstet Gynecol 2001;98:757.
10. Djurovic S, Clausen T, Wergeland R, et al. Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia. Br J Obstet Gynaecol 2002;109:759.
11. Savvidou MD, Lees CC, Parra M, et al. Levels of C-protein in pregnant women who subsequently develop preeclampsia. Br J Obstet Gynaecol 2002;109:297.
12. Qiu C, Luthy DA, Zhang C, et al. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. AJH 2004;17:154.
13. Belo L, Santos-Silva A, Pereira Leite L, et al. C-reactive protein and its potential involvement in the pathophysiology of preeclampsia. Fifth World Congress of Perinatal Medicine. 2001:417.
14. Teran E, Escudero C, Moya W, et al. Elevated C-reactive protein and pro-inflammatory cytochines in Andean women with pre-eclampsia. Int J Gynaecol Obstet 2001;75:243.
15. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A severe consequence of hypertension in pregnancy. Am J Obstet Gynaecol 1982;142:159.
16. Bernstei NI, Gabbe SG, Reed KL. Intrauterine Growth Restriction. In: Obstetrics. Normal and Problematic Pregnancies. Philadelphia: Churchill Livingstone, 2002:869.
17. Bek KM, Nielsen FR, Qvist I, et al. C-reactive protein (CRP) and pregnancy. An early indicator of chorioamnionitis. A review. Eur J Obstet Gynecol Reprod Biol 1990;35:29.
18. Nielsen FR, Bek KM, Rasmussen PE, et al. C-reactive protein during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 1990;35:23.
19. Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynecol 1998;105:11.
20. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and risk of developing hypertension. JAMA 2003;290:2945.
21. Sibai Baha M, Gordon T, Thom E, et al and the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Risk factors for preeclampsia in healthy nulliparous women: A prospective multicenter study. Am J Obstet Gynecol 1995;172:642.
22. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998;22:1145.
23. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42.
24. Chammas MF, Nguyen TM, Li MA, et al. Expectant management of severe preterm pre-eclampsia: Is intrauterine growth restriction an indication for immediate delivery? Am J Obstet Gynaecol 2000;183:853.
25. Paternoster M, Fantinato S, Manganelli F, et al. Efficacy of AT in pre-eclampsia: A case control prospective trial. Thromb Haemost 2004;91:283.
26. Maki M, Takao K, Toshihiko T, et al. Antithrombin therapy for severe preeclampsia: Results of a double-blind, randomised, placebo-controlled trial. Thromb Haemost 2000;84:583.
27. Martin JN, Perry KG, Blake PG, et al. Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. Am J Obstet Gynaecol 1997;177:1011.
28. Mecacci F, Carignani L, Cioni R, et al. Time course of recovery and complications of HELLP syndrome with two different treatments: Heparin or dexamethasone. Thromb Res 2001;102:99.
29. Paruk F, Moodley J. Maternal and neonatal outcome in early- and late-onset pre-eclampsia. Semin Neonatal 2000;5:197.